Galectin Therapeutics (GALT) Preferred Stock Liabilities (2011 - 2026)

Galectin Therapeutics' Preferred Stock Liabilities history runs 16 years deep, the most recent figure standing at $1.7 million for Q1 2026.

• In Q1 2026, Preferred Stock Liabilities changed 0.0% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $1.7 million (changed 0.0% YoY), while the FY2025 annual figure was $1.7 million, changed 0.0% from the prior year.
• Preferred Stock Liabilities was $1.7 million for Q1 2026 at Galectin Therapeutics, roughly flat from $1.7 million in the prior quarter.
• In the past five years, Preferred Stock Liabilities ranged from a high of $1.7 million in Q1 2022 to a low of $1.7 million in Q1 2022.
• Historically, Preferred Stock Liabilities has averaged $1.7 million across 5 years, with a median of $1.7 million in 2022.
• Biggest YoY gain for Preferred Stock Liabilities was 0.0% in 2022; the steepest drop was 0.0% in 2022.
• A 5-year view of Preferred Stock Liabilities shows it stood at $1.7 million in 2022, then changed by 0.0% to $1.7 million in 2023, then changed by 0.0% to $1.7 million in 2024, then changed by 0.0% to $1.7 million in 2025, then changed by 0.0% to $1.7 million in 2026.
• The last three Preferred Stock Liabilities figures came in at $1.7 million (Q1 2026), $1.7 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.